Morgan Stanley, CLSA cut Cipla ratings on earnings
MUMBAI (Reuters) - Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd (CIPL.NS) a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
(Reporting by Abhishek Vishnoi and Rafael Nam; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- World holds its breath, mostly hoping Scots vote "No"
- Scotland's independence vote: How will the results come?
- Chinese hackers breach U.S. military contractors -Senate probe
- UPDATE 1-Apple to unveil new iPads, operating system on Oct. 21 - report
- Chinese hacked U.S. military contractors, Senate probe finds
The Federal Reserve renewed its pledge to keep interest rates near zero for a "considerable time," but also indicated it could raise borrowing costs faster than expected when it starts moving. Article | Factbox
China cenbank injects $81 bln into major banks to support economy - reports Full Article